Skip to main content
Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma
Drug guidance

Polatuzumab vedotin for previously untreated diffuse large B-cell lymphoma

Cancer

Blood and Immune System

2 January 2024

Guidance Recommendations

Funding status

Back to top